Clinical Observation of Qingpeng Ointment Combined with Secukinumab Injection in the Treatment of Plaque Psoriasis
10.13359/j.cnki.gzxbtcm.2025.08.015
- VernacularTitle:青鹏软膏联合司库奇尤单抗注射液治疗斑块型银屑病临床观察
- Author:
Baochao YUAN
1
;
Xiaoling ZHANG
;
Guang ZHOU
Author Information
1. 安徽医科大学附属滁州市第一人民医院皮肤科,安徽 滁州 239000
- Keywords:
Qingpeng Ointment;
Secukinumab Injection;
plaque psoriasis;
skin lesion score;
quality of life;
inflammatory cytokines
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(8):1929-1936
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of Qingpeng Ointment(composed of Aconiti Penduli Radix,,Benzoinum,Artificial Moschus,Oxytropis Falcatae Herba,Rhei Pumili Radix Et Rhizoma,Fructus Phyllanthi,etc.)combined with Secukinumab Injection in treating patients with plaque psoriasis of blood stasis syndrome type.Methods From October 2022 to March 2024,a total of 86 patients diagnosed as plaque psoriasis of blood stasis syndrome type from the Department of Dermatology,Chuzhou First People's Hospital Affiliated to Anhui Medical University were enrolled.The patients were equally randomized into an observation group and a control group using a simplified randomization method,with 43 cases in each group.The control group received subcutaneous injection of Secukinumab Injection,while the observation group received additional topical application of Qingpeng Ointment based on the regimen for the control group.Both groups were treated for 3 months.The following parameters in both groups were assessed before and after treatment:the severity scores of skin lesion(including erythema,infiltration,and scale),traditional Chinese medicine(TCM)syndrome scores,quality of life scores,serum levels of inflammatory factors[interleukin 17A(IL-17A),interleukin 10(IL-10),vascular endothelial growth factor(VEGF)],and leukocyte p38 mitogen-activated protein kinase(MAPK)expression levels(including staining intensity scores and positive cell percentage scores).After treatment,the clinical efficacy and total incidence of adverse reactions were compared between the two groups.Results(1)After 3 months of treatment,the markedly-effective rate was 81.40%(35/43)in the observation group versus 58.14%(25/43)in the control group.The intergroup comparison showed significantly superior clinical efficacy in the observation group(χ2=8.378,P＜0.05).(2)After treatment,both groups exhibited significant reductions in the severity scores of skin lesion(including erythema,infiltration,and scale),TCM syndrome scores,quality of life scores,serum levels of inflammatory factors(IL-17A,IL-10,and VEGF),and expression levels of p38 MAPK in leukocytes(including staining intensity scores and positive cell percentage scores)(all P＜0.05),and the observation group demonstrated significantly greater reductions in all parameters than the control group(P＜0.05).(3)The total incidence of adverse reactions was 6.98%(3/43)in the observation group versus 13.95%(6/43)in the control group,showing no statistically significant intergroup difference(χ2=1.117,P＞0.05),and all adverse reactions in both groups resolved spontaneously within 1-2 day(s)after treatment.Conclusion Qingpeng Ointment combined with Secukinumab Injection demonstrates significant clinical efficacy in treating plaque psoriasis with blood stasis syndrome,and is effective on alleviating skin lesions and exerting anti-inflammatory effects through the suppression of leukocyte p38 MAPK expression.
